Statement re Completion of Acquisition (7050F)
May 03 2011 - 2:01AM
UK Regulatory
TIDMHIK
RNS Number : 7050F
Hikma Pharmaceuticals Plc
03 May 2011
Hikma completes the acquisition of Baxter Healthcare
Corporation's Multi-Source injectables business
-- Acquisition of Multi-Source Injectables significantly
enhances the scale and scope of Hikma's global Injectables
platform
-- Hikma to focus on quick and seamless integration for
customers and employees
London, 3 May 2011 - Hikma Pharmaceuticals PLC (LSE: HIK)
(NASDAQ DUBAI: HIK) ("Hikma"), the fast growing multinational
pharmaceutical group, announces that it has completed its $112
million acquisition of Baxter Healthcare Corporation's US generic
injectables business ("Multi-Source Injectables" or "MSI"),
significantly enhancing the scale and scope of its global
Injectables platform.
As required by the United States Federal Trade Commission, Hikma
will divest two West-Ward products, Phenytoin and Promethazine.
This will not have a material impact on Hikma's Injectables
revenues and will not affect the expected contribution from
Baxter's Multi-Source Injectables business.
"The acquisition of Baxter's MSI business is transformational
for Hikma, " said CEO Said Darwazah. "The acquisition doubles the
size of our global Injectables business and doubles our sales in
the US market, while further diversifying our global revenue base.
I am delighted to welcome our new employees and customers to
Hikma."
ENDS
Enquiries
Hikma Pharmaceuticals PLC +44 (0)20 7399 2760
Susan Ringdal, Investor Relations Director
Financial Dynamics +44 (0)20 7831 3113
Ben Atwell/Julia Phillips/Jonathan Birt/Matthew Cole
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics" based principally in the
Middle East and North Africa ("MENA") region, where it is a market
leader, the United States and Europe. In 2010, Hikma achieved
revenues of $731 million and profit attributable to shareholders of
$99 million. For news and other information, please visit
www.hikma.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACQPGUBUCUPGGQR
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024